Solventum Corporation (SOLV)
Automate Your Wheel Strategy on SOLV
With Tiblio's Option Bot, you can configure your own wheel strategy including SOLV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SOLV
- Rev/Share 48.2042
- Book/Share 28.6059
- PB 2.5096
- Debt/Equity 1.0303
- CurrentRatio 1.5
- ROIC 0.1814
- MktCap 12451587619.0
- FreeCF/Share 0.2869
- PFCF 249.0318
- PE 8.2106
- Debt/Assets 0.3676
- DivYield 0
- ROE 0.4104
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SOLV | UBS | -- | Neutral | -- | $77 | Oct. 1, 2025 |
| Initiation | SOLV | Jefferies | -- | Hold | -- | $80 | Sept. 11, 2025 |
| Upgrade | SOLV | Morgan Stanley | Equal Weight | Overweight | -- | $103 | July 15, 2025 |
| Upgrade | SOLV | Argus | Hold | Buy | -- | $90 | July 1, 2025 |
| Initiation | SOLV | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | June 6, 2025 |
| Upgrade | SOLV | Piper Sandler | Neutral | Overweight | -- | $87 | May 19, 2025 |
| Initiation | SOLV | Mizuho | -- | Neutral | -- | $70 | Dec. 4, 2024 |
| Initiation | SOLV | Stifel | -- | Buy | -- | $82 | Oct. 8, 2024 |
| Initiation | SOLV | Piper Sandler | -- | Neutral | -- | $71 | Oct. 7, 2024 |
| Initiation | SOLV | Wolfe Research | -- | Peer Perform | -- | -- | Sept. 26, 2024 |
News
Solventum (SOLV) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Solventum: A Mixed Q3 Provides Further Support For Our Neutral Stance
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Negative
Solventum which has barely moved since our coverage 14 months back, delivered mixed Q3 results last week. SOLV managed to beat both topline and bottomline estimates (although the degree of beat on the latter wasn't as strong as previous quarters), but revenue trends continue to slow. Margin pressures persist due to tariffs (the impact of which will be worse next year), but SOLV's new multi-year restructuring program and its ongoing efforts on programmatic savings may provetobehandy.
Read More
SOLV or DHR: Which Is the Better Value Stock Right Now?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
Read More
Unveiling Solventum (SOLV) Q3 Outlook: Wall Street Estimates for Key Metrics
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Solventum (SOLV) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Read More
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Solventum: A Solid Performance Here
Published: October 22, 2025 by: Seeking Alpha
Sentiment: Positive
Solventum Corporation looks increasingly attractive after divesting its Purification & Filtration business, reducing debt, and improving organic growth. SOLV raised the full-year earnings guidance twice, now projecting $5.88-$6.03 per share, reflecting solid momentum and successful execution. Despite a reasonable 12x earnings multiple and lower leverage, heavy earnings adjustments and spin-off costs temper near-term cash flow conversion.
Read More
SOLV or MEDP: Which Is the Better Value Stock Right Now?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Read More
SOLV or MEDP: Which Is the Better Value Stock Right Now?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Solventum (SOLV) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Read More
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Read More
Solventum Corporation (SOLV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Solventum Corporation (NYSE:SOLV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Wayde McMillan - Chief Financial Officer Garri Garrison - President of Health Information Systems Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Thanks. Welcome, everybody.
Read More
Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes").
Read More
Solventum Corporation (SOLV) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Solventum Corporation (NYSE:SOLV ) 2025 Wells Fargo Healthcare Conference September 5, 2025 10:15 AM EDT Company Participants Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Presentation Vikramjeet Chopra Associate Equity Analyst Okay. Good morning, everyone.
Read More
Solventum Announces $1.75 Billion Note Tender Offers
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
ST. PAUL, Minn. , Aug. 22, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) announced today that it has commenced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for up to $1.75 billion aggregate purchase price in cash (the "Aggregate Cap").
Read More
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.
Read More
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Negative
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
Read More
Ahead of Solventum (SOLV) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Solventum (SOLV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Solventum: Appealing Again
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimated at $5.50-$6.00 and leverage much lower post-divestment.
Read More
Is the Options Market Predicting a Spike in Solventum Stock?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to SOLV stock based on the movements in the options market lately.
Read More
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Read More
Solventum (SOLV) Just Overtook the 200-Day Moving Average
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.
Read More
Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript
Published: May 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - Chief Executive Officer Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Frederick Wise - Stifel, Nicolaus & Company, Inc. Jason Bednar - Piper Sandler & Co. David Roman - Goldman Sachs Group, Inc. Travis Steed - Bank of America Steven Valiquette - Mizuho Securities Operator Good afternoon. My name is Amy [ph] and I will be your conference call operator for …
Read More
Solventum Corporation: Cheap, With Caveats
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration, with a market cap of $11.5 billion. The company recently announced the sale of its Purification and Filtration business to Thermo Fisher at what seems a more than solid price.
Read More
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Read More
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
Read More
Solventum (SOLV) Soars 8.8%: Is Further Upside Left in the Stock?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Solventum (SOLV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
About Solventum Corporation (SOLV)
- IPO Date 2024-04-01
- Website https://www.solventum.com
- Industry Medical - Care Facilities
- CEO Bryan C. Hanson
- Employees 22000